nature.com - Maya Hassane, Youenn Jouan, Florent Creusat, Daphnée Soulard, Chloé Boisseau, Loïc Gonzalez, Emmanuel C. Patin, Nathalie Heuzé-Vourc’h, Jean-Claude Sirard, Christelle Faveeuw, François Trottein, Mustapha Si-Tahar, Thomas Baranek, Christophe Paget
This story originally appeared on Massive Science, an editorial partner site that publishes science stories by scientists. Subscribe to their newsletter to get even more science sent straight to you. international
Venture capitalists are investing $85 million to launch Arsenal Biosciences Inc., a cancer cellular-therapy startup led by the former president of heavily funded cancer-testing company Grail Inc. Ken is
What happens when desperate people with serious ailments or illnesses are promised an expensive miracle cure by an under-regulated industry? One year after wrapping up her last hit podcast, "Dr. Death"
Behind any landmark cure is years of medical research. But the old goal of research — to find a one-size-fits-all treatment for a disease, based on a set of standard protocols — must radically change further
More isn't necessarily better, at least for the excitation of brain cells. Three physician-scientists from the U.S. and Britain will share the prize. The U.S. Food and Drug Administration has been investigating